NCT03549208

A Study to Evaluate the Safety and Immunogeneicity of Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults

Single-blind, Single-center, Randomized, Active-controlled, Parallel Group, Phase I Study to Evaluate the Safety and Immunogenicity of Intramuscular Single Injection With Pneumococcal Conjugate Vaccine or Prevnar13 in Healthy Adults

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: LG Chem · Industry
• Sex: All
• Age: 19 Years – 50 Years
• Healthy volunteers: Accepted

Summary

phase-1 study pneumococcal conjugate vaccine study in healthy adults

Detailed description

A Study to Evaluate the Safety and Immunogeneicity of LBVE(Multivalent Pneumococcal Conjugate Vaccine) in Healthy adults

Conditions

• Pneumococcal Infection

Interventions

Type	Name	Description
BIOLOGICAL	LBVE01	Multivalent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
BIOLOGICAL	LBVE02	Multivalent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
BIOLOGICAL	Prevnar13	13-valent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh

Timeline

• Start date: 2018-07-01
• Primary completion: 2019-04-01
• Completion: 2019-07-25
• First posted: 2018-06-07
• Last updated: 2018-06-13